AU768002B2 - Immunotherapeutic composition and method for the treatment of prostate cancer - Google Patents

Immunotherapeutic composition and method for the treatment of prostate cancer Download PDF

Info

Publication number
AU768002B2
AU768002B2 AU41594/99A AU4159499A AU768002B2 AU 768002 B2 AU768002 B2 AU 768002B2 AU 41594/99 A AU41594/99 A AU 41594/99A AU 4159499 A AU4159499 A AU 4159499A AU 768002 B2 AU768002 B2 AU 768002B2
Authority
AU
Australia
Prior art keywords
binding agent
epitope
composition
specific antigen
prostate specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU41594/99A
Other languages
English (en)
Other versions
AU4159499A (en
Inventor
Beatrice Leveugle
Ragupathy Madiyalakan
Antoine A Noujaim
Birgit Schultes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoquest Inc
Original Assignee
Altarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Inc filed Critical Altarex Inc
Publication of AU4159499A publication Critical patent/AU4159499A/en
Application granted granted Critical
Publication of AU768002B2 publication Critical patent/AU768002B2/en
Assigned to ALTAREX MEDICAL CORP. reassignment ALTAREX MEDICAL CORP. Alteration of Name(s) in Register under S187 Assignors: ALTAREX CORP.
Assigned to ONCOQUEST INC. reassignment ONCOQUEST INC. Alteration of Name(s) in Register under S187 Assignors: ALTAREX MEDICAL CORP.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU41594/99A 1998-06-15 1999-06-15 Immunotherapeutic composition and method for the treatment of prostate cancer Ceased AU768002B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8928198P 1998-06-15 1998-06-15
US60/089281 1998-06-15
PCT/IB1999/001115 WO1999065523A1 (en) 1998-06-15 1999-06-15 Immunotherapeutic composition and method for the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
AU4159499A AU4159499A (en) 2000-01-05
AU768002B2 true AU768002B2 (en) 2003-11-27

Family

ID=22216751

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41594/99A Ceased AU768002B2 (en) 1998-06-15 1999-06-15 Immunotherapeutic composition and method for the treatment of prostate cancer

Country Status (9)

Country Link
US (3) US6881405B2 (https=)
EP (1) EP1085905B1 (https=)
JP (1) JP2002518347A (https=)
AT (1) ATE480566T1 (https=)
AU (1) AU768002B2 (https=)
CA (1) CA2328504A1 (https=)
DE (1) DE69942742D1 (https=)
IL (1) IL139700A (https=)
WO (1) WO1999065523A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US6881405B2 (en) * 1998-06-15 2005-04-19 Altarex Medical Corp. Reagents and methods for inducing an immune response to prostate specific antigen
PL201533B1 (pl) * 1999-01-13 2009-04-30 Igeneon Krebs Immuntherapie Zastosowanie przeciwciała skierowanego przeciwko antygenowi błony komórkowej Ep-CAM
IL152748A0 (en) 2000-05-11 2003-06-24 Altarex Inc Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
JP2005522483A (ja) * 2002-04-11 2005-07-28 アルタレックス メディカル コーポレーション 結合剤及び腫瘍細胞をターゲティングする際のそれらの使用
US20050271649A1 (en) * 2002-10-17 2005-12-08 Schultes Birgit C Therapeutic adjuvant
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20080095790A1 (en) * 2006-10-24 2008-04-24 Perambakam Supriya M Methods of Treating Prostate Cancer
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2331130B1 (en) 2008-04-09 2018-02-14 Oncoquest Inc. Ige antibodies for the treatment of cancer
ES2524699T3 (es) * 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
GB0811567D0 (en) * 2008-06-24 2008-07-30 Cytosystems Ltd Assay
EP3912643B8 (en) 2009-02-13 2023-08-23 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
US9023802B2 (en) * 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
SI2900277T1 (sl) 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN117138060A (zh) 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP4257134A3 (en) 2015-06-25 2024-01-24 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
US20250073349A1 (en) 2021-05-10 2025-03-06 Kawasaki Institute Of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
US4446122A (en) 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5053224A (en) 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
DE3650139T2 (de) 1985-07-05 1995-03-09 Hutchinson Fred Cancer Res Verfahren zum reduzieren der immunogenizität und zum induzieren immunologischer toleranz.
EP0234122A3 (en) 1986-02-21 1989-03-22 Oncogen Limited Partnership Tumor therapy with biologically active anti-tumor antibodies
AU613590B2 (en) 1986-11-19 1991-08-08 Bristol-Myers Squibb Company Hybridomas producing monoclonal antibodies to new mucin epitopes
US5059680A (en) 1986-11-24 1991-10-22 Centocor, Inc. Method of isolating ca 125 antigen
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
GB8728856D0 (en) 1987-12-10 1988-01-27 Bradwell A R Tumour-locating agents & method of locating tumours
EP0491867B1 (en) 1989-09-15 1996-11-27 Genetic Systems Corporation Hybridoma ct43 producing a monoclonal antibody to a mucin epitope of colorectal cancer
US5165922A (en) 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
DE4133791A1 (de) 1991-10-11 1993-04-15 Behringwerke Ag Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
GB9606228D0 (en) 1996-03-25 1996-05-29 Secr Defence Apparatus for matrix coating fibres with metal vapour
AU4086397A (en) 1996-09-06 1998-03-26 Centocor Inc. Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen
US6881405B2 (en) * 1998-06-15 2005-04-19 Altarex Medical Corp. Reagents and methods for inducing an immune response to prostate specific antigen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CORREAK P ET AL. JOURN NAT CANC INST VOL 89 NO 4 19 FEB 97 *
LEVEUGLE B ET AL. PROC AMERI ASSOC CANC RES VOL 39 1998 P355 *
VEMURA H ET AL. JOURN UROLO VOL 153 NO SUPPL 4 1995 P380A *

Also Published As

Publication number Publication date
US20020136715A1 (en) 2002-09-26
ATE480566T1 (de) 2010-09-15
CA2328504A1 (en) 1999-12-23
US6881405B2 (en) 2005-04-19
IL139700A (en) 2005-09-25
WO1999065523A1 (en) 1999-12-23
EP1085905A1 (en) 2001-03-28
JP2002518347A (ja) 2002-06-25
US7579445B2 (en) 2009-08-25
US20090220493A1 (en) 2009-09-03
DE69942742D1 (de) 2010-10-21
AU4159499A (en) 2000-01-05
IL139700A0 (en) 2002-02-10
EP1085905B1 (en) 2010-09-08
US20050202018A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
AU768002B2 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
US20080131443A1 (en) Method and composition for reconforming multi-epitopic antigens to intiate an immune response
ES2211877T3 (es) Linea celular linfoblastoide b humana que secreta un anticuerpo anti-gangliosido.
KR100771752B1 (ko) 항암 예방접종용 항체의 용도
JP2852705B2 (ja) 自己免疫疾患の治療
AU762699B2 (en) Therapeutic compositions that produce an immune response by altering the antigen
US20090202560A1 (en) Method for diagnosing efficacy of xenotypic antibody therapy
CA2253058A1 (en) Therapeutic composition that produce and immune response
US7361346B1 (en) Therapeutic compositions that produce an immune response
Ma et al. Characterization and evaluation of a novel anti-MUC-1 monoclonal antibody: induction of the idiotypic network in experimental mice
AU711270C (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
KR100372958B1 (ko) 면역반응을개시시키기위해다중에피토프항원의입체형태를변화시키기위한방법및조성물
JPH03504323A (ja) 抗体
NZ503032A (en) Use of a binding agent to reconforming multi-epitopic antigens to initiate an immune response

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTORS TO DELETE: BIRGIT SCHULTES

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTOR NAMES TO INCLUDE BIRGIT SCHULTES

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALTAREX MEDICAL CORP.

Free format text: FORMER OWNER WAS: ALTAREX CORP.